Thyrogen Articles
FDA advisory gives thumbs down for Zogenix' Zohydro for chronic pain; EU label extension for Genzyme's Thyrogen
10 December 2012
News briefs from Genzyme, Sagent, Orchid and Kyowa Hakko
14 November 2012
US FDA to take enforcement action regarding Genzyme’s Allston plant, including financial penalties
25 March 2010
Meeting highlights from Europe’s CHMP November 16-19, 2009
23 November 2009
FDA finds trash particles in Genzyme’s drugs, leading firm to advise health care providers
16 November 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Genzyme's 2008 profit down on costs
23 February 2009
Genzyme's 3rd-qtr 2008 profit down 25%
3 November 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
FDA clears Thyrogen for use in ablation
24 December 2007
Genzyme gets label change for Thyrogen
6 February 2006
Genzyme guidance upped on good 2nd qtr
25 July 2005
Genzyme's 1st-qtr revenues up 28%
25 April 2005
EC OKs new use for Genzyme's Thyrogen
14 March 2005
Stock Commentary - New York
14 March 2005
4th-qtr charges hit Genzyme General
17 March 2003
Genzyme's Thyrogen cleared in Canada
10 June 2002
Genzyme General to focus on therapeutics
8 March 1999
FDA Approves Genzyme's Thyrogen
3 December 1998
Knoll To Comarket Genzyme's Thyrogen
21 August 1998
Healthy Second-Quarter Growth For US Drug Firms
29 July 1998
Genzyme's Thyrogen Recommended For Approval
21 May 1998
Strong Revenue Growth At Genzyme General
11 March 1998
Genzyme's Thyrogen NDA Given Priority Review
26 February 1998
Genzyme General Files For Thyrogen Approval
18 December 1997
Genzyme Shares Rise On New Thyrogen Results
19 June 1997
Genzyme's Thyrogen Available In USA
21 November 1994
Genzyme's Thyrogen
3 October 1994
BIOTECH COMPANIES REPORT ON PROGRESS
16 May 1994
KIDDER, PEABODY ON BIOTECHNOLOGY
2 May 1994
BIOTECH PRODUCTS INUS DEVELOPMENT
26 July 1993
GENZYME BUYS BACK NEOZYME PROGRAMS
3 August 1992
GENZYME SEEKING EURO APPROVAL OF CEREDASE
13 April 1992
Showing 1-38 of 38 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
